Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced raising $135 million in Series A financing...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Vignette Bio in the transaction. Vignette Bio (“Vignette”) and EpimAb Biotherapeutics, Inc. (“EpimAB”) announced they have entered into...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Pipeline Therapeutics on the deal. Pipeline Therapeutics, a clinical-stage biopharmaceutical company, entered into a global license and development agreement with Janssen Pharmaceutica NV...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised Replicate Bioscience on the deal. Replicate Bioscience, a San Diego-based biotechnology company, announced its licensing agreement to collaborate with Precision NanoSystems, a developer of...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Brightseed on the deal. Brightseed, a San Francisco-based developer of plant nutrient technology, announced its $68 million Series B financing led by Temasek. Brightseed...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Xencor on the deal. Xencor, a clinical-stage biopharmaceutical company, announced its $100 million collaboration agreement with Johnson &...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Tarsus Pharmaceuticals, Inc. on the deal. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and...
You must be a Standard 1 Year member to access this content.
